menu
    • menu
    [{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fate Therapeutics \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"4","companyTruncated":"Fate Therapeutics \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Termination","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"FT576","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"ONO-8250","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Fate Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Fate Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Fate Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FT516","moa":"CD20","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FT516","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FT516","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FT536","moa":"CD16","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD16","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FT819","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"FT819","moa":"||CAR19 T-cell","graph1":"Immunology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FT819","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"FT825","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FT538","moa":"CD16","graph1":"Oncology","graph2":"Preclinical","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FT819","moa":"CAR19 T-cell","graph1":"Oncology","graph2":"IND Enabling","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Fate Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Fate Therapeutics

    Menu

    Fate Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : FT819,Cyclophosphamide

    Therapeutic Area : Immunology

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Fate Therapeutics Treats First Lupus Patient in Phase 1 Study of FT819 CAR T-Cell Program

    Details : FT819 is the first-ever, off-the-shelf, iPSC-derived CAR T-cell therapy, which is currently being evaluated for the treatment of moderate to severe active systemic lupus erythematosus.

    Product Name : FT819

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    September 05, 2024

    Lead Product(s) : FT819,Cyclophosphamide

    Therapeutic Area : Immunology

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : FT825

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Fate Therapeutics Initiates Phase 1 Trial for FT825 / ONO-8250 in Advanced Solid Tumors

    Details : ONO-8250 (FT825) is a multiplexed-engineered CAR T-cell candidate targeting HER2, under Phase 1 trials for HER2-expressing advanced solid tumors.

    Product Name : ONO-8250

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    August 01, 2024

    Lead Product(s) : FT825

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : FT576

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Sponsor : BofA Securities

    Deal Size : $100.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Fate Therapeutics Prices $100 Million Underwritten Offering and Private Placement

    Details : The Company plans to use net proceeds to fund clinical trials and nonclinical studies of its candidates, including FT576, an investigational CAR NK cell cancer immunotherapy.

    Product Name : FT576

    Product Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    March 19, 2024

    Lead Product(s) : FT576

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Sponsor : BofA Securities

    Deal Size : $100.0 million

    Deal Type : Public Offering

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : FT522,Cyclophosphamide

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Fate Presents FT522 Preclinical Data for Autoimmune Diseases At ASGCT

    Details : FT522 is an iPSC-derived CAR NK cell targeting CD19 with ADR technology, under evaluation for relapsed/refractory B-cell lymphoma.

    Product Name : FT522

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    March 05, 2024

    Lead Product(s) : FT522,Cyclophosphamide

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : FT576,Cyclophosphamide

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Sponsor : Johnson & Johnson Innovative Medicine

    Deal Size : $3,100.0 million

    Deal Type : Termination

    DEALS_DEV arrow-down

    Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next...

    Details : FT576 (CAR NK cells) is an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line. FT576 incorporates a proprietary CAR that targets BCMA, a novel high-affinity 158V and non-cleavable CD16 (hnCD16) F...

    Product Name : FT576

    Product Type : Cell and Gene therapy

    Upfront Cash : $100.0 million

    May 01, 2023

    Lead Product(s) : FT576,Cyclophosphamide

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Sponsor : Johnson & Johnson Innovative Medicine

    Deal Size : $3,100.0 million

    Deal Type : Termination

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : FT819,Cyclophosphamide

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at...

    Details : FT819 is an investigational, universal, off-the-shelf, T-cell receptor (TCR)-less CD19 chimeric antigen receptor (CAR) T-cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line.

    Product Name : FT819

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    October 12, 2022

    Lead Product(s) : FT819,Cyclophosphamide

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : FT536

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Cand...

    Details : FT536 also incorporates a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies; an IL-15 receptor fusion (IL-15RF) that augments...

    Product Name : FT536

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    October 01, 2022

    Lead Product(s) : FT536

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ONO-8250

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Ono Pharmaceutical

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candi...

    Details : Under the terms of the Collaboration and Option Agreement, the parties will jointly develop and commercialize FT825 (ONO-8250) in the U.S. and Europe, and ONO maintains exclusive development and commercialization rights for FT825 (ONO-8250) in the rest o...

    Product Name : FT825

    Product Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    July 11, 2022

    Lead Product(s) : ONO-8250

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Ono Pharmaceutical

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Ono Pharmaceutical

    Deal Size : Undisclosed

    Deal Type : Expanded Collaboration

    DEALS_DEV arrow-down

    ONO Announces Expanded Collaboration with Fate Therapeutics on iPSC-derived CAR-T Cell and CAR-NK Cell Therapi...

    Details : With this agreement, the discovery of iPSC-derived CAR-NK cell therapy will be added to iPSC-derived CAR-T cells therapy for solid tumors. And, a second new target for solid tumor collaboration has been added and ONO will provide Fate with antibodies tha...

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Undisclosed

    June 28, 2022

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Ono Pharmaceutical

    Deal Size : Undisclosed

    Deal Type : Expanded Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Fate Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : FT536,Cyclophosphamide

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the Society for Immuno...

    Details : FT536 is an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal master engineered iPSC line. FT536 incorporates a proprietary CAR that targets the α3 domain of MICA and MICB.

    Product Name : FT536

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    May 10, 2022

    Lead Product(s) : FT536,Cyclophosphamide

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth